Portfolio News

Belfast ‘tech for good’ company Inclutech has secured a £400,000 equity investment from Innovation Ulster Ltd (IUL) and Co-Fund III through Clarendon Fund Managers to accelerate commercialisation of its products.

Exciting progress from our portfolio company, Cumulus Neuroscience. At this year’s leading Alzheimer’s conference, they revealed that simple, at-home brain health tests can track Alzheimer’s more effectively than traditional clinic visits. It’s a big step toward faster, more accessible research—and a more human approach to clinical trials. Read more below.

Pilates reformer manufacturer Reform RX has become the first exit for the Investment Fund for Northern Ireland (IFNI) after the company was acquired by US-based connected fitness equipment leader iFIT Inc for an undisclosed sum.

The IFNI was launched by The British Business Bank to tackle an identified funding gap, with the aim of driving sustainable economic growth by supporting innovation and creating opportunities for new and scaling businesses.

Clarendon Fund Managers leads investment for data solutions firm INQDATA A data solutions company which hails Northern Ireland as a global centre of excellence when it comes to the talent of engineers has received £750,000 funding from the Investment Fund for Northern Ireland’s equity arm. The investment round into Belfast headquartered, INQDATA was led by

Portfolio company, Modern Democracy, ensures smooth running of GB elections for 4.5m voters as record number of Councils adopt digital check-in.Congratulations to Siobhan Donaghy and her team on delivering this great result for the recent GB elections. The below article is taken from: https://syncni.com/article/11966/derry-based-company-ensures-smooth-gb-elections-for-4-5m-voters-as-record-number-of-councils-adopt-digital-check-in Derry-based company Modern Democracy is forecasting further growth ahead of the

Neurovalens, a Belfast-headquartered specialist in non-invasive neuro-technology, has closed a £2.1m funding round with existing investors in preparation for a $40m-$50m Series B fundraising round. The firm has also received clearance from the US Food & Drug Administration (FDA) for its Modius Stress device. The below article is taken from: https://www.insidermedia.com/news/ireland/neurovalens-closes-2.1m-funding-round?utm_source=ireland_newsletter&utm_campaign=ireland_news_tracker&utm_medium=deals_article The company, whose medical

Congratulations to portfolio company, The Boatyard Distillery and, in particular, Joe McGirr and Declan McGurk, on this significant recognition. The Drinks International Report is seen as the global authority for the spirits world with the top 100 bars globally contributing to its publication. Boatyard climbed the rankings of both the top trending Vodka and Gin lists, and also made

Congratulations to portfolio company, CV6 Therapeutics, (NI) Ltd. and, in particular, Robert D. Ladner, Ph.D. on this significant commercial milestone. We look forward to following developments with interest as the company commences its first-in-human clinical trial. Article taken from: CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial (yahoo.com) CV6 Therapeutics

Congratulations to portfolio company, Neurovalens, and its CEO, Jason McKeown, on receiving clearance from the FDA on its Modius Sleep device for the treatment of chronic insomnia! A big milestone for the company – well done to the whole Neurovalens team! Article taken from: https://www.massdevice.com/fda-clears-insomnia-treating-device-neurovalens/ Neurovalens announced today that the FDA granted clearance to its Modius Sleep device for treating chronic